Skip to content

Total debt at other companies

Vericel logo
VericelVCEL
$95.04M-4.6%
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$411.18M+15.3%
Bioventus logo
BioventusBVS
$288.42M-21.2%
Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
$15M-34.9%
Stryker logo
StrykerSYK
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH

Other financials

Income statement

See full
Revenue$29.6M+13.2%
Net income-$5.1M-3.8%

Balance sheet

See full
Cash & equivalents$41.0M-23.1%
Total equity$133.9M-9.8%
Total assets$179.4M-5.9%

Cash flow

See full
Operating cash flow-$4.8M-3,628%
CapEx$1.4M-49.3%
Free cash flow-$6.3M-112%

Valuation

See full
Market cap$204.37M+31.6%
Enterprise value$189.09M+48.7%
P/S1.8×+0.1×

Profitability

See full
Net margin-9.8%-4.4pp
FCF margin0.9%

Returns & leverage

See full
Return on equity-8%-3.4pp
Debt / equity0.2×0.0×
Current ratio4.5×-1.3×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $25.74M.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Anika Therapeutics's total debt?
Anika Therapeutics (ANIK) reported total debt of $25.74M in Q1 2026.
How has Anika Therapeutics's total debt changed year-over-year?
Anika Therapeutics's total debt increased by 1.2% year-over-year, from $25.44M to $25.74M.
What is the long-term trend for Anika Therapeutics's total debt?
Over 5 years (2020 to 2025), Anika Therapeutics's total debt has grown at a 3.2% compound annual growth rate (CAGR), from $22.38M to $26.25M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.